Ho M, Paruzzo L, Noll JH, Stella F, Devi P, Ndeupen S, Chen GM, Cohen IJ, Ramirez-Fernandez A, Waxman A, Kapur S, Chen F, Xu R, Huff A, Jarocha D, Patel V, Bochi-Layec AC, Ramasubramanian R, Liu S, Bouvier R, De Souza VB, Petal H, Li Z, Carturan A, Michener P, Hopkins CR, Koucky O, Minehart J, Dimitri A, Nabar NR, Hasanali ZS, Ciccarelli B, Willians E, Bartoszek R, Lavorando M, Suyash M, Gonzalez VE, Porazzi P, Bhoj V, Apostolidis SA, Vogl DT, Porter DL, Scholler J, Diorio C, Roche AM, Everett JK, Bushman FD, Nathanson KL, Stadtmauer EA, Susanibar-Adaniya SP, Garfall AL, Ruella M*, Cohen AD*, Fraietta JA*. CD4⁺ T-cells mediate ‘CART-associated Immune-Related Adverse Events’ (CirAE) after BCMA CAR T Therapy , Nature Medicine: 2025
Yu KL, Ho M, Paruzzo L, Stella F, Patel H, Hasanali Z, Kapur S, Waxman AJ, Vogl DT, Stadtmauer EA, Fraietta JA, Ruella M, Cohen AD, Garfall AL, Susanibar-Adaniya S Outcomes of relapse after teclistamab therapy in multiple myeloma , Blood Cancer Journal: 2025
Musa H, Mielnik M, Trudel S, Weisel K, Mockus-Daehn T, Ferron-Brady G, Hong Q, Ma Y, Pater S, Suchindran S, Zhou X, Richardson PG, Cohen AD*, Lowther DE* No evidence of B-cell maturation antigen loss or systemic immune impairment following belantamab mafodotin treatment in multiple myeloma , Haematologica: 2025
Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, Deol A, Agha M, Berdeja JG, Lesokhin AM, Liegel JJ, Rossi A, Lieberman-Cribbin A, Usmani SZ, Dhakal B, Parekh S, Li H, Wang F, Montes de Oca R, Plaks V, Sun H, Banerjee A, Schecter JM, Lendvai N, Madduri D, Lengil T, Zhu J, Koneru M, Akram M, Patel N, Costa Filho O, Jakubowiak AJ, Voorhees PM Long-Term (5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma , Journal of Clinical Oncology, 43: 2025,2766-71
Ho M, Paruzzo L, Minehart J, Voruganti T, Devi P, Vogl DT, Cohen AD, Garfall AL, Waxman AJ, Kapur S, Stadtmauer EA, Adaniya SS, Longworth S Non-tuberculous mycobacterial infections following teclistamab in multiple myeloma , Haematologica, 110: 2025,1436-42
98., Jadlowsky JK, Hexner EO, Marshall A, Grupp SA, Frey NV, Riley JL, Veloso E, McConville H, Rogal W, Czuczman C, Hwang WT, Li Y, Leskowitz RM, Farrelly O, Karar J, Christensen S, Barber-Rotenberg J, Gaymon A, Aronson N, Bernstein W, Melenhorst JJ, Roche AM, Everett JK, Zolnoski SA, McFarland AG, Reddy S, Petrichenko A, Cook EJ, Lee C, Gonzalez VE, Alexander K, Kulikovskaya I, Ramírez-Fernández Á, Minehart JC, Ruella M, Gill SI, Schuster SJ, Cohen AD, Garfall AL, Shah PD, Porter DL, Maude SL, Levine BL, Siegel DL, Chew A, McKenna S, Lledo L, Davis MM, Plesa G, Herbst F, Stadtmauer EA, Tebas P, DiNofia A, Haas A, Haas NB, Myers R, O'Rourke DM, Svoboda J, Tanyi JL, Aplenc R, Jacobson JM, Ko AH, Cohen RB, June CH, Bushman FD, Fraietta JA Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies , Nature Medicine, 31: 2025,1134-1144
Chen GM, Gering D, Satulovsky J, Datta S, Lai P, Karar J, Gonzalez VE, Alexander K, Chew A, Jadlowsky JK, Moody, Carolan E, Ruella M, Paruzzo L, Amses KR, Stadtmauer EA, Frey NV, Hexner EO, Porter DL, Cohen AD, Gill SI, Garfall AL, Schuster SJ, Mo K, Liang SI, Spasic M, Levine BL, Siegel DL, Ramirez-Fernandez A, Mackall CL, Bushman FD, Good Z, Wherry EJ, June CH, Fraietta JA Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-hematologic cancer , Nature Biomedical Engineering: 2025
Stalker M, Garfall A, Cohen AD, Vogl DT, Djulbegovic M, Susanibar-Adaniya S, Stadtmauer E, Megherea O, Waxman AJ Safety and efficacy of teclistamab in patients with relapsed or refractory AL amyloidosis: a retrospective case series , European Journal of Haematology, 114: 2025,443-447
Costa LJ, Banerjee R, Mian H, Weisel KC, Bal S, Derman BA, Htut MM, Nagarajan C, Rodriguez C, Richter J, Frigault MJ, Ye JC, van de Donk NWCJ, Voorhees PM, Puliafito B, Bahlis N, Popat R, Chng WJ, Ho PJ, Kaur G, Kapoor P, Du J, Schjesvold F, Berdeja J, Einsele H, Cohen AD, Mikhael J, Biru Y, Rajkumar SV, Lin Y, Martin TG, Chari A International Myeloma Working Group Immunotherapy Committee Recommendation on Sequencing Immunotherapy for Treatment of Multiple Myeloma , Leukemia, 39: 2025,543-554
Gaballa MR, Puglianini OC, Cohen A, Vogl D, Chung A, Ferreri CJ, Voorhees P, Hansen DK, Patel KK BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement , Blood Advances, 9: 2025,1171-1180
